Collegium Pharmaceutical (NASDAQ:COLL) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14), Briefing.com reports. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The business had revenue of $70.20 million for the quarter, compared to analyst estimates of $74.79 million. During the same period last year, the business posted ($0.45) EPS. Collegium Pharmaceutical’s revenue was up 485.0% on a year-over-year basis.
COLL opened at $15.42 on Friday. The company has a market cap of $514.27 million, a price-to-earnings ratio of -6.24 and a beta of 0.24. Collegium Pharmaceutical has a 52 week low of $12.49 and a 52 week high of $29.90. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94.
Several brokerages have recently weighed in on COLL. BidaskClub raised Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 4th. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. Cantor Fitzgerald set a $35.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, September 21st. Janney Montgomery Scott set a $27.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 6th. Finally, HC Wainwright reissued a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $31.71.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the transaction, the director now owns 361,000 shares of the company’s stock, valued at $5,967,330. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 25.76% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Trexquant Investment LP purchased a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $504,000. BlackRock Inc. grew its stake in shares of Collegium Pharmaceutical by 7.0% in the 3rd quarter. BlackRock Inc. now owns 2,409,573 shares of the specialty pharmaceutical company’s stock valued at $35,517,000 after purchasing an additional 157,300 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Collegium Pharmaceutical by 8.1% in the 3rd quarter. Janus Henderson Group PLC now owns 4,119,823 shares of the specialty pharmaceutical company’s stock valued at $60,726,000 after purchasing an additional 309,477 shares during the last quarter. Prudential Financial Inc. grew its stake in shares of Collegium Pharmaceutical by 49.3% in the 3rd quarter. Prudential Financial Inc. now owns 430,240 shares of the specialty pharmaceutical company’s stock valued at $6,342,000 after purchasing an additional 142,000 shares during the last quarter. Finally, C WorldWide Group Holding A S grew its stake in shares of Collegium Pharmaceutical by 115.7% in the 3rd quarter. C WorldWide Group Holding A S now owns 319,750 shares of the specialty pharmaceutical company’s stock valued at $4,713,000 after purchasing an additional 171,506 shares during the last quarter. 94.41% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Collegium Pharmaceutical (COLL) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/10/collegium-pharmaceutical-coll-posts-quarterly-earnings-results-misses-expectations-by-0-14-eps.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.